CA3082839A1 - Methods of inhibiting tumor metastasis - Google Patents

Methods of inhibiting tumor metastasis Download PDF

Info

Publication number
CA3082839A1
CA3082839A1 CA3082839A CA3082839A CA3082839A1 CA 3082839 A1 CA3082839 A1 CA 3082839A1 CA 3082839 A CA3082839 A CA 3082839A CA 3082839 A CA3082839 A CA 3082839A CA 3082839 A1 CA3082839 A1 CA 3082839A1
Authority
CA
Canada
Prior art keywords
cancer
thromboxane
receptor antagonist
6alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3082839A
Other languages
English (en)
French (fr)
Inventor
Jill M. Pulley
Robert R. Lavieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CA3082839A1 publication Critical patent/CA3082839A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3082839A 2017-11-29 2018-11-29 Methods of inhibiting tumor metastasis Pending CA3082839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592365P 2017-11-29 2017-11-29
US62/592,365 2017-11-29
PCT/US2018/062967 WO2019108736A1 (en) 2017-11-29 2018-11-29 Methods of inhibiting tumor metastasis

Publications (1)

Publication Number Publication Date
CA3082839A1 true CA3082839A1 (en) 2019-06-06

Family

ID=66664589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3082839A Pending CA3082839A1 (en) 2017-11-29 2018-11-29 Methods of inhibiting tumor metastasis

Country Status (9)

Country Link
US (4) US11471444B2 (https=)
EP (1) EP3716973A4 (https=)
JP (1) JP7305197B2 (https=)
KR (1) KR102687556B1 (https=)
CN (2) CN111432817B (https=)
AU (1) AU2018375378A1 (https=)
CA (1) CA3082839A1 (https=)
TW (1) TW201924719A (https=)
WO (1) WO2019108736A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220164000A (ko) * 2020-03-31 2022-12-12 어플라이드 메디칼 테크놀로지스 엘엘씨 Pgd2/dp2 및 트롬복산 a2/tp 수용체의 이중 길항제 및 이상 면역 반응 또는 혈전성 체질의 치료를 위한 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066480A (en) 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
US4839384A (en) 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
US5153327A (en) 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5100889A (en) 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
ZA911453B (en) 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5158967A (en) * 1991-06-12 1992-10-27 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5281716A (en) * 1992-06-18 1994-01-25 Bristol-Myers Squibb Company Method for preparing 7-oxabicycloheptyl substituted oxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds
US5260449A (en) 1992-08-12 1993-11-09 E. R. Squibb & Sons, Inc. Method for preparing 7-oxabicycloheptyl substituted bromooxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
US5332840A (en) 1993-05-27 1994-07-26 Bristol-Myers Squibb Company Method for preparing a benzaldehyde intermediate
US5605917A (en) 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
IL137937A0 (en) 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
AU2001264729A1 (en) * 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
EP1986675A2 (en) 2006-02-24 2008-11-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
US20080160024A1 (en) 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
WO2009089098A1 (en) 2008-01-03 2009-07-16 Musc Foundation For Research Development Methods for the treatment of cancers
US9283266B2 (en) 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8912167B2 (en) 2011-05-19 2014-12-16 Eugene J. Oliva Heparin-based compositions and methods for the inhibition of metastasis
US20170226514A1 (en) 2014-08-13 2017-08-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prevention of tumour metastasis by inhibition of necroptosis

Also Published As

Publication number Publication date
CN117122687A (zh) 2023-11-28
JP2021504385A (ja) 2021-02-15
EP3716973A1 (en) 2020-10-07
US20250144079A1 (en) 2025-05-08
CN111432817A (zh) 2020-07-17
KR20200093575A (ko) 2020-08-05
AU2018375378A1 (en) 2020-05-28
KR102687556B1 (ko) 2024-07-22
US20240041839A1 (en) 2024-02-08
US11471444B2 (en) 2022-10-18
US20230090578A1 (en) 2023-03-23
WO2019108736A1 (en) 2019-06-06
US20200405694A1 (en) 2020-12-31
JP7305197B2 (ja) 2023-07-10
CN111432817B (zh) 2023-10-31
EP3716973A4 (en) 2021-11-10
TW201924719A (zh) 2019-07-01

Similar Documents

Publication Publication Date Title
TWI660952B (zh) 抗增生化合物及其使用方法
JP2024522736A (ja) がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
BR112013014708B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
AU2019223906B2 (en) Methods of use for trisubstituted benzotriazole derivatives
TW201410247A (zh) 醫藥組合
JP2018533560A (ja) 癌を治療するための併用療法
CN103841976A (zh) Akt和mek抑制剂化合物的组合及其使用方法
JP2024535913A (ja) Ｋｒａｓ変異を有するがん患者の治療
US20250144079A1 (en) Methods of inhibiting tumor metastasis
ES3037447T3 (en) The compound of formula (i) and ponatinib for use in the treatment of chronic myeloid leukemia with bcr-abl mutations
BR112014022266A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com outros compostos antitumor
KR102275112B1 (ko) 5-브로모-인디루빈
WO2015019320A1 (en) Pim kinase inhibitor combinations
AU2022358409A1 (en) Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor
JP2019519573A (ja) がんを処置するための方法
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
CN113811302A (zh) 激酶抑制剂的用途
HK40033357A (en) Methods of inhibiting tumor metastasis
KR102959095B1 (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
US20230404998A1 (en) Combination Therapies for Treating Cancer
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
WO2025229051A1 (en) Use of atr inhibitors in combination with antiandrogen agent
HK40029947A (en) Antiproliferative compounds and methods of synthesizing thereof
HK40030002B (zh) 癌症疗法
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231129

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250404

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250717

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260127